2 型糖尿病市场规模、份额和成长分析（按给药途径、分销管道、最终用户和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，全球 2 型糖尿病市场规模将达到 367 亿美元，到 2025 年将达到 395.3 亿美元，到 2033 年将达到 716.7 亿美元，预测期（2026-2033 年）的复合年增长率为 7.72%。

全球第2型糖尿病市场正经历显着成长，主要驱动因素是全球盛行率的不断上升。对有效治疗方法日益增长的需求促使製药公司不断创新并推出新的治疗方法。其中，钠-葡萄糖共同输送体2 (SGLT2) 抑制剂和Glucagon-Like Peptide-1(GLP-1) 受体促效剂因其疗效显着且副作用较少，已成为首选治疗方法。然而，患者对这些新治疗方法的认知度仍有不足，这可能会阻碍其广泛应用。对价格合理、先进的糖尿病管理解决方案的需求不断增长，为市场扩张创造了巨大的机会。此外，包括行动医疗应用和云端解决方案在内的技术进步正在革新治疗方式，使全球患者更容易获得有效的治疗选择。

全球第2型糖尿病市场驱动因素

全球第二型糖尿病市场的主要驱动因素之一是全球肥胖和久坐生活方式的日益普遍。肥胖率的上升导致第2型糖尿病发病率的增加，从而刺激了对有效治疗方法和管理方案的需求。遗传因素和饮食习惯进一步加剧了病例的激增，促使人们更加关注健康并采取预防措施。因此，製药公司和医疗保健机构正大力投资于创新治疗方法、监测设备和教育计画的研发，从而建构了一个以对抗这种慢性疾病为核心的强大市场格局。

限制全球第2型糖尿病市场的因素

全球第2型糖尿病市场的主要限制因素之一是病患和医疗保健系统日益关注药物带来的经济负担。糖尿病管理药物（包括胰岛素和口服降血糖药）价格的不断上涨构成了一大障碍，尤其是在中低收入地区。这种经济负担会导致患者对处方治疗的依从性降低，最终导致更差的健康状况。此外，预算限制可能会限制医疗服务提供者开立最佳治疗方法，这可能会阻碍市场成长潜力以及第二型糖尿病新型有效治疗方法的创新。

全球第2型糖尿病市场趋势

全球第2型糖尿病市场正经历着向远端监测和数位化医疗解决方案的重大转变，这主要得益于穿戴式技术和行动应用程式的整合应用。这些创新使患者能够持续监测血糖值，并与医疗服务提供者即时共用数据，从而实现主动疾病管理。更完善的血糖值追踪、药物顺从性和整体健康管理不仅能改善病患预后，也有助于降低医疗成本。此外，这一趋势提高了患者的参与度，最终将糖尿病护理转变为更个人化和高效的体验，也反映了医疗保健领域向科技融合的更广泛趋势。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争格局概述

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 影响市场的因素
• 关键投资机会
• 生态系测绘
• 市场吸引力指数（2025）
• PESTEL 分析
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 技术评估

全球第2型糖尿病市场规模（依药物类别及复合年增长率划分）（2026-2033年）

• Dipeptidyl Peptidase-4抑制剂
• 类升糖素肽-1受体促效剂
• 比瓜尼德斯
• 钠-葡萄糖共同输送体2 (SGLT2) 抑制剂
• 其他的

全球第2型糖尿病市场规模（依给药途径及复合年增长率划分）（2026-2033年）

• 口服
• 肠外

全球第2型糖尿病市场规模（依通路划分）及复合年增长率（2026-2033年）

• 医院药房
• 零售药房
• 网路药房

全球第2型糖尿病市场规模（依最终用户划分）及复合年增长率（2026-2033年）

• 居家医疗环境
• 医院和诊所
• 学术和研究机构
• 其他的

全球第2型糖尿病市场规模及复合年增长率（2026-2033年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Medtronic
• B. Braun Melsungen AG
• Abbott Laboratories
• F. Hoffmann-La Roche
• Insulet Corporation

结论与建议

Global Type 2 Diabetes Market size was valued at USD 36.7 Billion in 2024 and is poised to grow from USD 39.53 Billion in 2025 to USD 71.67 Billion by 2033, growing at a CAGR of 7.72% during the forecast period (2026-2033).

The global type 2 diabetes market is experiencing significant growth, primarily driven by the surging prevalence of the condition worldwide. This escalating demand for effective treatments has prompted pharmaceutical companies to innovate and introduce new therapies. Notable advancements include sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, which have emerged as preferred options due to their efficacy and reduced side effects. However, a gap remains in patient awareness regarding these new treatments, potentially hindering their adoption. The increasing need for affordable and advanced diabetes management solutions creates substantial opportunities for market expansion. Furthermore, technological advancements, including mobile health applications and cloud-based solutions, are revolutionizing treatment delivery, making effective options more accessible to patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Type 2 Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Type 2 Diabetes Market Segments Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Type 2 Diabetes Market

One of the key market drivers for the global Type 2 diabetes market is the increasing prevalence of obesity and sedentary lifestyles among populations worldwide. As obesity rates rise, the incidence of Type 2 diabetes escalates, prompting a growing demand for effective treatments and management solutions. This surge in cases is further fueled by genetic factors and dietary habits, leading to heightened awareness and proactive health measures. Consequently, pharmaceutical companies and healthcare providers are investing significantly in research and development of innovative therapies, monitoring devices, and educational programs, creating a robust market landscape focused on combating this chronic condition.

Restraints in the Global Type 2 Diabetes Market

One key market restraint for the global Type 2 diabetes market is the rising prevalence of drug affordability concerns among patients and healthcare systems. The increasing cost of diabetes management medications, including insulin and oral antidiabetic agents, poses significant barriers, particularly in low and middle-income regions. This financial strain can lead to non-adherence to prescribed treatments, ultimately resulting in poorer health outcomes. Moreover, healthcare providers may face limitations in prescribing optimal therapies due to budget constraints, thereby hindering the market's growth potential and innovation in new, effective treatment options for Type 2 diabetes.

Market Trends of the Global Type 2 Diabetes Market

The global Type 2 Diabetes market is experiencing a significant shift towards remote monitoring and digital health solutions, driven by the integration of wearable technologies and mobile applications. These innovations empower patients to continuously monitor their glucose levels and share real-time data with healthcare providers, fostering proactive disease management. Enhanced tracking of blood sugar levels, medication adherence, and overall health not only improves patient outcomes but also contributes to reduced healthcare costs. Furthermore, this trend stimulates increased patient engagement, ultimately transforming diabetes care into a more personalized and efficient experience, which reflects a broader movement towards technological integration in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Type 2 Diabetes Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like Peptide 1 Receptor Agonists
• Biguanides
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
• Others

Global Type 2 Diabetes Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral

Global Type 2 Diabetes Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Type 2 Diabetes Market Size by End User & CAGR (2026-2033)

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Global Type 2 Diabetes Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations